Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 9:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 3,591 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Carcinoma, Bronchogenic Clear all
Completed Phase 2 Interventional Results available

MEK162 for Patients With RAS/RAF/MEK Activated Tumors

NCT01885195
View directory record Official record
Conditions
Solid Tumor and Hematologic Malignancies
Interventions
MEK162
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
68
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 24, 2026, 9:44 AM EDT
Terminated No phase listed Observational Results available

Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lung Cancer

NCT02762877
View directory record Official record
Conditions
Non Small Cell Lung Carcinoma
Interventions
Not listed
Lead sponsor
Genomic Health®, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
Torrance, California • Macon, Georgia • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 24, 2026, 9:44 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy

NCT06139627
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
Interventions
Best Practice, Biospecimen Collection, Communication Intervention, Comprehensive Geriatric Assessment, Electronic Health Record Review, Survey Administration
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
60 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2031
U.S. locations
3
States / cities
Duarte, California • Rochester, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 24, 2026, 9:44 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)

NCT02331251
View directory record Official record
Conditions
Advanced Cancer, Breast Cancer, Sarcoma, Pancreatic Cancer, Small Cell Lung Cancer, Ovarian
Interventions
Pembrolizumab, Gemcitabine, Docetaxel, Nab-paclitaxel, Vinorelbine, Irinotecan, Liposomal Doxorubicin
Drug
Lead sponsor
Western Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Goodyear, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 24, 2026, 9:44 AM EDT
Withdrawn Phase 2 Interventional

A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel

NCT00768131
View directory record Official record
Conditions
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions
Cetuximab, Paclitaxel, Carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
14
States / cities
Little Rock, Arkansas • Long Beach, California • Boynton Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 24, 2026, 9:44 AM EDT
Completed Phase 2 Interventional Results available

A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer

NCT01788566
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Necitumumab, Gemcitabine, Cisplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Birmingham, Alabama • Deerfield Beach, Florida • Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Oct 24, 2026, 9:44 AM EDT
Terminated Phase 2 Interventional Results available

Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC

NCT04926831
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
capmatinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
La Jolla, California • Sacramento, California • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 24, 2026, 9:44 AM EDT
Recruiting Phase 1 Interventional

Study of XB010 in Subjects With Solid Tumors

NCT06545331
View directory record Official record
Conditions
Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer), Hormone-receptor-positive Breast Cancer, Triple Negative Breast Cancer (TNBC)
Interventions
XB010, Pembrolizumab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Irvine, California • Los Angeles, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 24, 2026, 9:44 AM EDT
Completed Phase 1 Interventional

Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

NCT04344795
View directory record Official record
Conditions
Solid Tumor, Colorectal Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Endometrial Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma, Solid Tumors With PIK3Ca Mutation
Interventions
TPST-1495 twice daily, TPST-1495 once daily or on intermittent schedule, Pembrolizumab
Drug
Lead sponsor
Tempest Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
11
States / cities
Aurora, Colorado • Baltimore, Maryland • Springfield, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 24, 2026, 9:44 AM EDT
Completed Phase 1 Interventional

Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma

NCT00413075
View directory record Official record
Conditions
Solid Tumor, Lymphoma
Interventions
oral belinostat
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
4
States / cities
New Haven, Connecticut • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 24, 2026, 9:44 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer

NCT00266877
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Interventions
HKI-272
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
11
States / cities
Los Angeles, California • Zion, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 24, 2026, 9:44 AM EDT
Completed Phase 2 Interventional

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

NCT04736173
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
Interventions
Domvanalimab, Zimberelimab, Carboplatin, Paclitaxel, Pemetrexed, Pembrolizumab
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Columbus, Georgia • Kingwood, Texas • Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 24, 2026, 9:44 AM EDT
Completed Not applicable Interventional

Vaccine Therapy, Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed With Surgery

NCT00091039
View directory record Official record
Conditions
Lung Cancer
Interventions
recombinant fowlpox GM-CSF vaccine adjuvant, recombinant fowlpox-CEA(6D)/TRICOM vaccine, recombinant vaccinia-CEA(6D)-TRICOM vaccine, carboplatin, paclitaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 24, 2026, 9:44 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer

NCT00653939
View directory record Official record
Conditions
Tumors
Interventions
Fosbretabulin, Carboplatin, Paclitaxel, Bevacizumab
Drug
Lead sponsor
Mateon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
15
States / cities
Campbell, California • Fountain Valley, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2015 · Synced Oct 24, 2026, 9:44 AM EDT
Not listed Phase 2 Interventional

Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004

NCT00285675
View directory record Official record
Conditions
Androgen Independent Prostate Cancer (AIPC), Non Small Cell Lung Cancer (NSCLC)
Interventions
DN-101 (calcitriol) - Drug
Drug
Lead sponsor
Novacea
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
11
States / cities
Berkeley, California • San Francisco, California • Vallejo, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 31, 2006 · Synced Oct 24, 2026, 9:44 AM EDT
Terminated Phase 2 Interventional Results available

Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer

NCT02590003
View directory record Official record
Conditions
Carcinoma, Non-small Cell Lung
Interventions
Carboplatin, Nab-paclitaxel
Drug
Lead sponsor
Yale University
Other
Eligibility
71 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 24, 2026, 9:44 AM EDT
Not yet recruiting Early Phase 1 Interventional

Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy

NCT06979661
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Cancer, Lung Cancer Recurrent
Interventions
Haystack™ ctDNA Assay
Diagnostic Test
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 24, 2026, 9:44 AM EDT
Completed Phase 1 Interventional

Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer

NCT00954278
View directory record Official record
Conditions
Carcinoma, Non Small Cell Lung
Interventions
sorafenib
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 24, 2026, 9:44 AM EDT
Completed Not applicable Interventional Results available

Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy

NCT01209520
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Carcinoma, Hypermethylation
Interventions
Cisplatin, Carboplatin, Paclitaxel, Vidaza, Tumor Specimen for Methylation Analysis, Blood Sample for Methylation Analysis, Vinorelbine, Docetaxel, Pemetrexed
Drug · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 24, 2015 · Synced Oct 24, 2026, 9:44 AM EDT
Completed Phase 1 Interventional

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

NCT03319459
View directory record Official record
Conditions
HER2 Positive Gastric Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, EGFR Positive Solid Tumor, Advanced Solid Tumors, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Pancreatic Cancer, Melanoma
Interventions
FATE-NK100, Cetuximab, Trastuzumab
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
San Diego, California • Minneapolis, Minnesota • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 24, 2026, 9:44 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

NCT03126110
View directory record Official record
Conditions
Advanced Malignancies, Metastatic Cancer
Interventions
INCAGN01876, Nivolumab, Ipilimumab
Drug
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
15
States / cities
Los Angeles, California • Gainesville, Florida • Detroit, Michigan + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 24, 2026, 9:44 AM EDT
Terminated Phase 1Phase 2 Interventional

Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

NCT05860296
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic
Interventions
SLC-391, pembrolizumab
Drug · Biological
Lead sponsor
SignalChem Lifesciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Indianapolis, Indiana • Lafayette, Indiana • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 24, 2026, 9:44 AM EDT
Recruiting Phase 2 Interventional

TOP 2301: Neoadjuvant Chemo for NSCLC

NCT06385262
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Alirocumab, Cemiplimab, Chemotherapy
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 24, 2026, 9:44 AM EDT
Completed Phase 3 Interventional Results available

A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).

NCT00863746
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Sorafenib (Nexavar, BAY43-9006), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
703 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
3
States / cities
Fayetteville, Arkansas • Stanford, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 19, 2015 · Synced Oct 24, 2026, 9:44 AM EDT